Subsequent cohort studies have demonstrated its upregulation in multiple malignancies, including NSCLC 12, breast cancer 13, and leukemia 14, and that high LAPTM4B expression correlates with poor prognosis 12-14. This evidence concerns the gene LAPTM4B and non-small cell lung carcinoma.